Stockreport

Septerna, in market debut, surges at open [Seeking Alpha]

Septerna, Inc.  (SEPN) 
PDF The pharma's lead candidate is SEP-786, a PTH1R agonist in phase 1 for hypoparathyroidism. In a prior SEC filing, Septerna said it planned to offer ~11M shares at $15 [Read more]